NCT Number: NCT02273453
Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets
Study to determine the presence of a hang-over effect in healthy volunteers the day after the administration of Songha® Night
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–60 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy male or female Caucasian subjects aged 20-60 years
- Normal outcome in Pittsburgh Sleep Quality Index (PSQI), below mean +2 Standard Deviation (SDs)
- No manifest sleep disorder diagnosed by polysomnography
- Normal pupillary function
- Willing and able to give written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to participation in the study and able to perform the study during the full time period of 36 days
Exclusion criteria
- Subjective sleep duration of less than 3 hours in the night before the test
- Caffeine, nicotine or alcohol on the day (from midnight) of the test
- Alcohol consumption on the evening before visits 3, 5 or 7
- Eye-drops or other drugs, taken orally or intravenously, influencing pupil size or motility
- Shift work
- Drug and alcohol abuse
- Use of psycho-active drugs during the past 30 days
- Any treatment that might interfere with the evaluation of the test drug
- Any drug known to interact with benzodiazepines and related drugs, e.g. antiepileptics, antihistaminics, muscle relaxant drugs, antihypertensive drugs, drugs inhibiting cytochrome P450
- Any serious disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
- Known hypersensitivity to any of the ingredients of the study drugs
- Pregnant or nursing women or inadequate birth control methods (this applies to female of childbearing potential only)
- Participation in another trial within the past 30 days
Treatment and study plan
Oxazepam
DrugPlacebo
DrugPrimary outcomes
-
Changes from baseline of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test
Time frame: 08:00h, 09:30h, 11:00h at Day 7 of each treament period
Secondary outcomes
-
Change of the Pupillary Unrest Index (PUI) measured by pupillographic sleepiness test
Time frame: up to day 36
-
Change in subjective sleepiness rated on a 7 point scale
Time frame: up to day 36
Stanford Sleepiness Scale
-
Change in subjective sleepiness measured on a visual analogue scale (VAS)
Time frame: up to day 36
-
Change in sleep quality measured on a visual analogue scale (VAS)
Time frame: up to day 36
-
Global Assessment of tolerability by investigator on 4-point scale
Time frame: Day 36
-
Global Assessment of tolerability by patient on 4-point scale
Time frame: Day 36
-
Number of subjects with adverse events
Time frame: up to 36 days
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm)
Important dates
- Study start
- 2003
- Primary completion
- 2003
- First posted
- Oct 24, 2014
- Registry last updated
- Oct 24, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details